Bharat Biotech, University of Sydney Sign MoU for Vaccine Research

In a significant step towards advancing vaccine research initiatives and strengthening global efforts to combat infectious diseases, Bharat Biotech International, a leading vaccine manufacturer and the University of Sydney Infectious Diseases Institute (SydneyID) have signed a Memorandum of Understanding (MoU). This collaboration aims to foster academic-industry partnerships, design novel methodologies for tackling future epidemics and leverage the strengths of both entities to advance the science of vaccines and biotherapeutics.

Building Strong Collaborations

The agreement underscores the commitment of Bharat Biotech and the University of Sydney to building strong sectoral and cross-organizational collaborations. By pooling their resources and expertise, the two entities seek to develop innovative approaches to address infectious diseases and epidemics. The collaboration also aims to create a framework for sustained cooperation in the field of vaccine research.

Mutual Excitement for Shared Vision

Executive Chairman of Bharat Biotech, Krishna Ella, expressed mutual excitement about the collaboration, stating, “Mutually, we are excited about the new opportunities to strengthen our shared vision, leverage the prowess of education, research capabilities to help build a healthier universe and improve people’s lives by developing safer vaccine platforms.” This highlights the shared commitment of both organizations to contribute to global health through cutting-edge research and development.

Global Impact on Health

Sydney ID Deputy Director Jamie Triccas emphasized the significance of the collaboration, stating, “Together with Bharat Biotech International, we aim to make a lasting impact on global health.” This partnership extends beyond national boundaries, with a focus on leveraging collective knowledge and resources to address global health challenges. The collaboration is poised to contribute to the development of solutions that have a far-reaching impact on improving public health globally.

Expertise and Product Portfolio

Bharat Biotech, with a robust product portfolio comprising 19 vaccines, including the indigenously developed COVID-19 vaccine Covaxin, brings extensive expertise to the collaboration. The company has been at the forefront of vaccine development and has played a pivotal role in the fight against the COVID-19 pandemic. Sydney ID, as a key partner in the Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) contract, further strengthens the collaboration with its focus on advancing vaccine research and development.

CEPI-Supported Consortium

Syndey ID leads a vaccine consortium, supported by the Coalition for Epidemic Preparedness Innovations (CEPI), uniting the University of Sydney, Bharat Biotech and ExcellGene. This consortium is dedicated to developing a broadly protective SARS- CoV-2 vaccine, highlighting the commitment of the collaborating entities to addressing current and emerging global health threats.